Pertussis vaccination in patients with respiratory illness

Research Review CPD-Accredited E-Learning Module

Begin

Pertussis vaccination in patients with respiratory illness

This Research Review E-Learning Module is intended for New Zealand GPs and covers pertussis (whooping cough) vaccination in individuals with respiratory illness such as asthma or COPD. It is based on the Research Review Educational Series publication of the same title.


Before starting the module please read the Research Review Educational Series publication, accessed through the link below:

Pertussis vaccination in patients with respiratory illness

The PDF can be viewed on screen, saved and printed through the link above. 

This E-Learning Module covers:

  • Pertussis epidemiology pathophysiology
  • Clinical course and burden of disease of pertussis
  • Pertussis in patients with respiratory compromise
  • Immunisation against pertussis
  • Funded pertussis vaccines in New Zealand
  • Immunisation schedules and length of immunity

Learning outcomes

After completing this module you should have an improved understanding of:

  • Pertussis epidemiology pathophysiology
  • Clinical course and burden of disease of pertussis
  • Pertussis in patients with respiratory compromise
  • Immunisation against pertussis
  • Funded pertussis vaccines in New Zealand
  • Immunisation schedules and length of immunity

Contributing experts

Expert commentary has been provided by Professor Lutz Beckert, a respiratory physician at Canterbury DHB, and by Dr Mike Maze, a respiratory and infectious diseases physician, also at Canterbury DHB. 

Module questions have been developed by Dr Chris Tofield who works part time in General Practice in Tauranga, New Zealand, is involved in clinical research and is a clinical advisor to the Bay of Plenty District Health Board.

Accreditation

“Pertussis vaccination in patients with respiratory illness” E-Learning Module has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes.
Further info

References

  1. New Zealand National Immunisation Schedule. Available from: https://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/new-zealand-immunisation-schedule (Accessed June 2020)
  2. Pharmac. Decision to widen access to pertussis (whooping cough) vaccine. Available from: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-pertussis-whooping-cough-vaccine/ (Accessed June 2020)
  3. The Immunisation Advisory Centre. Available from: https://www.immune.org.nz (Accessed June 2020)
  4. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev. 1993;15(2):265–302
  5. European Centre for Disease Prevention and Control. Expert consultation on pertussis –Barcelona, 20 November 2012. Stockholm: ECDC; 2014.
  6. World Health Organization. Pertussis vaccines. WHO position paper Wkly. Epidemiol Rec. 2010;85:385-400
  7. van der Lee S et al. Whole-cell or acellular pertussis primary immunizations in infancy determines adolescent cellular immune profiles. Front Immunol. 2018;9:51
  8. Chisholm H et al. Pertussis vaccination failure in the New Zealand pediatric population: Study protocol. Vaccines (Basel). 2019;7(3):65
  9. ESR Pertussis Report. May 2019. Available from: https://surv.esr.cri.nz/PDF_surveillance/PertussisRpt/2019/PertussisReportMay2019.pdf (Accessed June 2020)
  10. Todar K. Bordetella pertussis and whooping cough. Madison (WI): Todar’s Online Textbook of Bacteriology; 2009. Available from http://textbookofbacteriology.net/pertussis.html (Accessed June 2020)
  11. Blasi F et al. The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context. Hum Vaccin Immunother. 2020;16(2):340–348
  12. Liu BC et al. Pertussis in older adults: Prospective study of risk factors and morbidity. Clin Infect Dis. 2012;55(11):1450-6
  13. Bouza E et al. Vaccines for the prevention of infections in adults: an opinion paper on the situation in Spain. Rev Esp Quimioter 2019;32(4):333-64
  14. Peters MJ et al. Mechanisms of pulmonary hypertension in Bordetella pertussis. Arch Dis Child. 2003;88(1):92-93
  15. Ministry of Health. Immunisation Handbook 2017 (2nd Edition, March 2018). Available from: https://www.health.govt.nz/publication/immunisation-handbook-2017 (Accessed June 2020)
  16. De Serres G et al. 2000 Morbidity of pertussis in adolescents and adults. J Infect Dis. 2000;182(1):174-79
  17. Mattoo S and Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005;18(2):326-82
  18. Capili CR et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol. 2012;129(4):957-63
  19. Karki S et al. Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case-control study. Vaccine. 2015;33(42):5647-5653
  20. Buck PO et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: An analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109–2121
  21. Kandeil W et al. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines 2019;18(5):439-55
  22. Harju TH et al. Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax. 2006;61(7):579–584
  23. Mbayei SA et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69(2):218–226
  24. INFANRIX-hexa Medsafe data sheet. Available from: https://www.medsafe.govt.nz/Profs/Datasheet/I/Infanrixhexainj.pdf (Accessed June 2020)
  25. INFANRIX- IPV Medsafe data sheet. Available from: https://www.medsafe.govt.nz/Profs/Datasheet/i/InfanrixIPVinj.pdf (Accessed June 2020)
  26. Boostrix Medsafe data sheet. Available from: https://www.medsafe.govt.nz/profs/datasheet/b/Boostrixinj.pdf (Accessed June 2020)
  27. Adacel® Medsafe data sheet. Available from: https://www.medsafe.govt.nz/profs/datasheet/a/adacelinj.pdf (Accessed June 2020)
  28. Halperin SA et al. Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 10 years after a previous dose. J Pediatric Infect Dis Soc. 2019;8(2):105-114
  29. Tseng HF et al. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013;56(3):315–321
  30. Chen Z and He Q. Immune persistence after pertussis vaccination. Hum Vaccin Immunother. 2017;13(4):744-56